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Letters to the Editor
Calcium channel blocker use and
gastrointestinal tract bleeding
among older adults
SIR—Several studies have reported that the incidence
of gastrointestinal (GI) tract bleeding is increased about
two-fold m people usmg calcium channel blockers
(CCBs) [1—3] CCBs have powerful vasodilatory effects
They may also affect platelet function [4] and red blood
cell defbrmability [5] when taken orally at Standard
doses Therefore, the hypothesis that these agents may
mcrease the nsk of bleeding is biologically plausible We
conducted an ancillary strudy m the Cardiovascular
Health Study (CHS) cohort of older adults to examme
the association between the use of CCBs and GI
bleeding
The CHS is a prospective cohort study established
in 1989/90 of 5,888 people aged 65 years and older
in four commumties in the United States of America,
selected from Medicare ehgibility lists [6] At study
baseline and annually dunng follow-up, participants
completed questionnaires that mcluded Information
about their medical history and were exammed at a
study clinic Medication use was collected by an
inventory method at baseline and at annual mtervals
Hospital admissions were identified from several
sources, mcluding Medicare bilhng records and semi-
annual subject contacts We identified and validated via
chart review all hospitakzations from study baseline
dunng March 1998 contaimng discharge diagnoses for
gastnc, duodenal, pepüc, or gastrojejunal ulcer with
bleeding, rectal bleeding, haematemesis, melaena, or GI
bleeding not otherwise specified We excluded bleeding
events that occurred after the third day of hospitaliza-
tion, or that were due to a procedure or surgery We
were not able to capture non-hospitahzed GI bleeding
m this study
Durmg an average follow-up of 51 years, we
identified 121 validated hospitabzed GI bleeding events
in treated hypertensive subjects that were confirmed
upon review (32% of potential events were not con-
firmed) Hypertensive subjects who used CCBs had
an incidence of GI bleeding of 9 9/1,000 person-years,
compared with a rate of 6 1/1,000 person-years m those
who used other antihypertensive agents [age-adjusted
Cox hazard raüo = l 62, 95% confidence mterval
(CI) = 1 13—232] After also adjustmg for cardiovascular
disease history, the hazard ratio associated with CCB use
was 137 (95% CI=095-1 98) Further adjustment
for GI bleeding nsk factors such äs sex, aspirm use,
and oral anticoagulation had kttle effect Analyses limited
to subjects who received monotherapy for hypertension
found that CCB users tended to have a higher incidence
of bleeding than subjects usmg other types of anti-
hypertensive medicaüons, though results were not
statistically significant Highei CCB doses were not
associated with higher bleeding risk, on the contrary,
those usmg lower doses had higher nsk Each of the
three major CCB types (dihydropyridines, phenyl-
alkylammes, and benzothlazepmes) was associated with
a slight but non-significant elevation in risk, and the
hazard ratio was l 85 for immediate-release CCB formu-
lations and 117 for sustained-release CCB formulations
When we limited the analysis to events that met pre-
specified cnteria for 'hfe-tbreatening' bleeding (»=45
events), the hazard ratio associated with CCB use was
l 98 (95% CI=1 08-363) The hazard ratio associated
with CCB use was not significantly different across strata
defined by use of other medications, suggesting an
absence of synergism
In summary, among hypertensive subjects 65 years
and older m an epldemiological cohort study, there was
a 62% mcrease in nsk of GI tract bleeding among
users of CCBs, but after adjustmg for pre-existing
cardiovascular disease, the mcrease in risk was 37% and
was of borderlme statistical sigmficance An important
limitation of this observational study is the lack of
random assignment of CCBs and other antihypertensive
medications Some randomized placebo-controlled con-
trolled trials have suggested an increased occurrence of
bleeding events with CCBs [7, 8], while others have not
[9] We note that mcomplete ascertamment of bleeding
events may have limited the abihty of previous clmical
trials to assess adequately whether CCBs cause bleeding
complications For example, the overall incidence of
all types of bleeding (excluding cerebral or retmal
haemorrhage) reported among the hypertensive patients
60 years or older in the Syst-Eur nitrendipme trial was
33/1,000 person years [9] By contrast, m the present
cohort of older adults with hypertension, we found
an incidence of 7 5/1,000 person-years for hospitahzed
gastrointestinal bleeding alone Even a relatively low rate
of bleeding complications might affect the overall balance
of nsks and benefits of CCB therapy m older patients
with hypertension For this reason, it would be prudent
to mclude bleeding äs a pre-specified, prospectively
collected endpomt m ongomg and future randomized
controlled trials of calcium channel blockmg-agents
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